CN110398589B - Kit for quantitatively detecting content of anti-mullerian hormone and detection method thereof for non-disease diagnosis purpose - Google Patents
Kit for quantitatively detecting content of anti-mullerian hormone and detection method thereof for non-disease diagnosis purpose Download PDFInfo
- Publication number
- CN110398589B CN110398589B CN201910701278.4A CN201910701278A CN110398589B CN 110398589 B CN110398589 B CN 110398589B CN 201910701278 A CN201910701278 A CN 201910701278A CN 110398589 B CN110398589 B CN 110398589B
- Authority
- CN
- China
- Prior art keywords
- mullerian hormone
- solution
- monoclonal antibody
- magnetic beads
- reaction tube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a kit for quantitatively detecting the content of anti-mullerian hormone and a detection method thereof for non-disease diagnosis purposes, wherein the kit comprises NHS magnetic bead suspension, anti-mullerian hormone monoclonal antibody I, anti-mullerian hormone monoclonal antibody II, coupling buffer solution, confining solution, enhancing solution, cleaning solution and calibrator; the invention combines the sensitivity of time-resolved fluorescence immunoassay and the rapidity of magnetic separation technology, the detection method is simple and convenient to operate, the detection time is greatly shortened, the repeatability is good, and the method can be widely used for clinical detection.
Description
Technical Field
The invention relates to the field of in-vitro diagnosis, in particular to a kit for quantitatively detecting the content of anti-mullerian hormone and a detection method thereof for non-disease diagnosis.
Background
Anti-mullerian hormone, also known as AMH, is a direct product of early ovarian follicles, a glycoprotein dimer consisting of two 72KDa monomers linked by a disulfide bridge, secreted by the granulosa cells of female ovarian tissue. AMH is initially expressed in a granular cell layer of a primary follicle, is most strongly expressed in pre-antral follicles with the diameter of about 0.1-0.2 mm and small antral follicles with the diameter of about 2mm, and is gradually weakened to completely disappear in the antral follicles with the diameter of more than 4mm, so that the AMH has an important regulation effect on follicular development, the serum AMH level is not influenced by pituitary gonadotropins, and the change of the value is small in the whole menstrual cycle.
Compared with the conventional method for predicting ovarian reserve and ovarian reactivity (age, antral follicle number, follicle stimulating hormone, estradiol and the like) which is commonly used at present, the blood AMH value can be generated in real time, and the ovarian reserve function can be accurately and sensitively reflected. Has incomparable advantages in the aspects of monitoring ovarian reserve capacity, diagnosing ovarian related diseases, predicting IVF success rate, preventing OHSS complications and the like. AMH is the most ideal biomarker for predicting ovarian response and evaluating ovarian reserve function at present.
For the detection of AMH, current clinical methods include: enzyme linked immunosorbent assay, chemiluminescence, electrochemiluminescence and other methods. Currently, the most common enzyme-linked immunosorbent assay method is to detect the anti-mullerian hormone content by using an enzyme-linked immunosorbent assay method, has high sensitivity and strong specificity, but has long detection time and can not be automated; the chemiluminescence method for detecting the AMH in the serum can realize automatic detection, but needs an expensive chemiluminescence detection system. In the traditional time-resolved fluoroimmunoassay method, the combination of an antibody and a capture substance on a microporous plate is slow, and the immunomagnetic beads are uniformly dispersed in a solution, so that the contact area with the antibody is increased, thereby increasing the combination rate of the immunomagnetic beads and the antibody, greatly improving the specific surface area of a detection reaction and shortening the detection time.
Disclosure of Invention
The invention aims to provide a kit for quantitatively detecting the content of anti-mullerian hormone and a detection method thereof for non-disease diagnosis, which have the advantages of strong specificity, short detection time, quick and simple operation, capability of obtaining results in a short time and the like.
In order to achieve the purpose, the invention provides the following technical scheme: a kit for quantitatively detecting the content of anti-mullerian hormone comprises an NHS magnetic bead suspension, an anti-mullerian hormone monoclonal antibody I, an anti-mullerian hormone monoclonal antibody II, a coupling buffer solution, a sealing solution, an enhancement solution, a cleaning solution and a calibrator.
The detection method of the kit for quantitatively detecting the content of the anti-mullerian hormone for non-disease diagnosis purposes comprises the following steps:
(1) diluting anti-mullerian hormone monoclonal antibody I with coupling buffer solution to the concentration of more than or equal to 20 ug/mL;
(2) putting 100 mu L of NHS magnetic bead suspension into a reaction tube, carrying out magnetic separation, reserving NHS magnetic beads, and discarding supernatant; add 500. mu.L of coupling buffer into the reaction tube and vortex for 15 s; performing magnetic separation, keeping NHS magnetic beads, and discarding supernatant;
(3) adding 1mL of diluted anti-mullerian hormone monoclonal antibody I into a reaction tube, vortexing for 30s, and uniformly mixing NHS magnetic beads; placing the reaction tube on a rotary mixer, and incubating for 2h at room temperature;
(4) after the incubation is finished, performing magnetic separation, discarding the supernatant, and keeping the NHS magnetic beads; adding 1mL of confining liquid into a reaction tube, swirling for 20s, placing the reaction tube on a rotary mixer, incubating for 1h at room temperature, performing magnetic separation, discarding the supernatant, and retaining NHS magnetic beads; finally, adding 1mL of cleaning solution into the reaction tube, carrying out vortex for 20s, carrying out magnetic separation, discarding the supernatant, and keeping the NHS magnetic beads; repeating the cleaning step for 1 time; obtaining magnetic beads coupled with the anti-mullerian hormone monoclonal antibody I, adding a preservation solution, and preserving at 4 ℃ for later use;
(5) 500 mu L of anti-mullerian hormone monoclonal antibody II and 200 mu L of Eu are taken3+adding-DTPA into a reaction tube, and carrying out magnetic stirring reaction at 25 ℃ for 24h to obtain Eu3+Labeled anti-mullerian hormone monoclonal antibody II, Eu3+Purifying the marked anti-mullerian hormone monoclonal antibody II by using a protein column and storing for later use;
(6) sequentially adding magnetic beads coupled with anti-mullerian hormone monoclonal antibody I, 50 muL of calibrator or serum to be tested and 150 muL of Tris-HCL reaction buffer solution into a 96-hole microplate, carrying out oscillation incubation at 25 ℃ for 5min, standing for 2min, retaining the magnetic beads coupled with anti-mullerian hormone monoclonal antibody I, and discarding supernatant; repeating the above cleaning step with cleaning solution for 5 times; then 200 mul of Eu are added3+Labeled anti-mullerian hormone monoclonal antibody II, and performing shaking incubation at 25 ℃ for 5 min; repeating the above cleaning step with cleaning solution for 5 times; adding 200 μ L of enhancing solution, and incubating at 25 deg.C for 5 min; and detecting by using a time-resolved fluorescence immunoassay analyzer.
The coupling buffer was sodium carbonate buffer at a concentration of 0.2M, pH 8.3.3.
The cleaning solution contains 8mmol/L NaCl, 0.1% BSA, 0.2% bovine serum albumin, 0.1mol/L Tween-80 and 0.1% NaN3Tris-HCl buffer (50mmol/L, pH 7.8).
The blocking solution was 1% BSA in PBS buffer (0.02M, pH 7.4).
The preservation solution is Tris-HCl buffer (0.05M, pH 8.0) containing 5% BSA, 10% trehalose, 0.1% Tween-20.
The enhancement solution is an aqueous solution containing 0.03% of sodium acetate, 0.0002-0.0009% of beta-NTA, 0.0024% of TOPO, 0.08% of acetic acid, 0.1% of absolute ethyl alcohol and 0.05% of Triton X-100.
The detection principle of the time-resolved fluoroimmunoassay quantitative detection AMH kit is a sandwich method, wherein magnetic beads coupled with anti-mullerian hormone monoclonal antibody I are firstly added into a 96-hole microplate, a calibrator or serum to be detected is added into a reaction hole, 150 mu L of Tris-HCL reaction buffer solution is subjected to oscillatory incubation at 25 ℃ for 5min, and the incubation is carried out for 2 min. After multiple washing, 200 μ L of Eu is added3+And (3) forming an immunomagnetic bead-antigen-europium label/samarium label antibody complex by using the labeled anti-mullerian hormone monoclonal antibody II. After washing, adding the enhancement solution, under the action of exciting light, the fluorescent substance emits light signals with certain wavelength, and the light signals are identified by the time-resolved immunofluorescence analyzer, so that the more the detected object is in the sample, the stronger the intensity of the generated fluorescence signals is. And (3) simulating a calibration curve of the AMH concentration and the fluorescence signal value, and calculating the AMH concentration according to the luminous intensity value of the sample to be detected.
The invention has the following beneficial effects: the invention combines the sensitivity of time-resolved fluorescence immunoassay and the rapidity of magnetic separation technology, the detection method is simple and convenient to operate, the detection time is greatly shortened, the repeatability is good, and the method can be widely used for clinical detection.
Drawings
FIG. 1 shows the time-Eu for high purity enhancing fluid and common enhancing fluid3+The graphs are counted.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below.
Example 1
A kit for quantitatively detecting the content of anti-mullerian hormone comprises an NHS magnetic bead suspension, an anti-mullerian hormone monoclonal antibody I, an anti-mullerian hormone monoclonal antibody II, a coupling buffer solution, a sealing solution, an enhancement solution, a cleaning solution and a calibrator.
The detection method of the kit for quantitatively detecting the content of the anti-mullerian hormone for non-disease diagnosis purposes comprises the following steps:
(1) diluting anti-mullerian hormone monoclonal antibody I with coupling buffer solution to the concentration of 20 ug/mL;
(2) putting 100 mu L of NHS magnetic bead suspension into a reaction tube, carrying out magnetic separation, reserving NHS magnetic beads, and discarding supernatant; add 500. mu.L of coupling buffer into the reaction tube and vortex for 15 s; performing magnetic separation, keeping NHS magnetic beads, and discarding supernatant;
(3) adding 1mL of diluted anti-mullerian hormone monoclonal antibody I into a reaction tube, vortexing for 30s, and uniformly mixing NHS magnetic beads; placing the reaction tube on a rotary mixer, and incubating for 2h at room temperature;
(4) after the incubation is finished, performing magnetic separation, discarding the supernatant, and keeping the NHS magnetic beads; adding 1mL of confining liquid into a reaction tube, swirling for 20s, placing the reaction tube on a rotary mixer, incubating for 1h at room temperature, performing magnetic separation, discarding the supernatant, and retaining NHS magnetic beads; finally, adding 1mL of cleaning solution into the reaction tube, carrying out vortex for 20s, carrying out magnetic separation, discarding the supernatant, and keeping the NHS magnetic beads; repeating the cleaning step for 1 time; obtaining magnetic beads coupled with the anti-mullerian hormone monoclonal antibody I, adding a preservation solution, and preserving at 4 ℃ for later use;
(5) 500 mu L of anti-mullerian hormone monoclonal antibody II and 200 mu L of Eu are taken3+adding-DTPA into a reaction tube, and carrying out magnetic stirring reaction at 25 ℃ for 24h to obtain Eu3+Labeled anti-mullerian hormone monoclonal antibody II, Eu3+Purifying the marked anti-mullerian hormone monoclonal antibody II by using a protein column and storing for later use;
(6) sequentially adding magnetic beads coupled with anti-mullerian hormone monoclonal antibody I, 50 muL of calibrator or serum to be tested and 150 muL of Tris-HCL reaction buffer solution into a 96-hole microplate, carrying out oscillation incubation at 25 ℃ for 5min, standing for 2min, retaining the magnetic beads coupled with anti-mullerian hormone monoclonal antibody I, and discarding supernatant; repeating the above cleaning step with cleaning solution for 5 times; then 200 mul of Eu are added3+Labeled anti-mullerian hormone monoclonal antibody II, and performing shaking incubation at 25 ℃ for 5 min; repeating the above cleaning step with cleaning solution for 5 times; adding 200 μ L of enhancing solution, and incubating at 25 deg.C for 5 min; and detecting by using a time-resolved fluorescence immunoassay analyzer.
Further, the coupling buffer was sodium carbonate buffer at a concentration of 0.2M, pH 8.3.3.
Further, the cleaning solution isContains 8mmol/L NaCl, 0.1% BSA, 0.2% bovine serum albumin, 0.1mol/L Tween-80, and 0.1% NaN3Tris-HCl buffer (50mmol/L, pH 7.8).
Further, the blocking solution was 1% BSA in PBS buffer (0.02M, pH 7.4).
Further, the preservation solution was Tris-HCl buffer (0.05M, pH 8.0) containing 5% BSA, 10% trehalose, 0.1% Tween-20.
Furthermore, the enhancement liquid is a common brand on the market, and the brand is Jiangyuan.
The detection principle of the time-resolved fluoroimmunoassay quantitative detection AMH kit is a sandwich method, wherein magnetic beads coupled with anti-mullerian hormone monoclonal antibody I are firstly added into a 96-hole microplate, a calibrator or serum to be detected is added into a reaction hole, 150 mu L of Tris-HCL reaction buffer solution is subjected to oscillatory incubation at 25 ℃ for 5min, and the incubation is carried out for 2 min. After multiple washing, 200 μ L of Eu is added3+And (3) forming an immunomagnetic bead-antigen-europium label/samarium label antibody complex by using the labeled anti-mullerian hormone monoclonal antibody II. After washing, adding the enhancement solution, under the action of exciting light, the fluorescent substance emits light signals with certain wavelength, and the light signals are identified by the time-resolved immunofluorescence analyzer, so that the more the detected object is in the sample, the stronger the intensity of the generated fluorescence signals is. And (3) simulating a calibration curve of the AMH concentration and the fluorescence signal value, and calculating the AMH concentration according to the luminous intensity value of the sample to be detected.
Example 2
The embodiment provides another detection method of a kit for quantitatively detecting the content of anti-mullerian hormone for non-disease diagnosis purposes, which comprises the following steps:
(1) diluting anti-mullerian hormone monoclonal antibody I with coupling buffer solution to the concentration of 30 ug/mL;
(2) putting 100 mu L of NHS magnetic bead suspension into a reaction tube, carrying out magnetic separation, reserving NHS magnetic beads, and discarding supernatant; add 500. mu.L of coupling buffer to the reaction tube and vortex for 35 s; performing magnetic separation, keeping NHS magnetic beads, and discarding supernatant;
(3) adding 1mL of diluted anti-mullerian hormone monoclonal antibody I into a reaction tube, vortexing for 30s, and uniformly mixing NHS magnetic beads; placing the reaction tube on a rotary mixer, and incubating for 2h at room temperature;
(4) after the incubation is finished, performing magnetic separation, discarding the supernatant, and keeping the NHS magnetic beads; adding 1mL of confining liquid into a reaction tube, swirling for 50s, placing the reaction tube on a rotary mixer, incubating for 1h at room temperature, performing magnetic separation, discarding supernatant, and retaining NHS magnetic beads; finally, adding 1mL of cleaning solution into the reaction tube, carrying out vortex 50s, carrying out magnetic separation, removing the supernatant, and keeping the NHS magnetic beads; repeating the cleaning step for 1 time; obtaining magnetic beads coupled with the anti-mullerian hormone monoclonal antibody I, adding a preservation solution, and preserving at 4 ℃ for later use;
(5) 500 mu L of anti-mullerian hormone monoclonal antibody II and 200 mu L of Eu are taken3+adding-DTPA into a reaction tube, and carrying out magnetic stirring reaction at 25 ℃ for 24h to obtain Eu3+Labeled anti-mullerian hormone monoclonal antibody II, Eu3+Purifying the marked anti-mullerian hormone monoclonal antibody II by using a protein column and storing for later use;
(6) sequentially adding magnetic beads coupled with anti-mullerian hormone monoclonal antibody I, 50 muL of calibrator or serum to be tested and 150 muL of Tris-HCL reaction buffer solution into a 96-hole microplate, carrying out oscillation incubation at 25 ℃ for 5min, standing for 2min, retaining the magnetic beads coupled with anti-mullerian hormone monoclonal antibody I, and discarding supernatant; repeating the above cleaning step with cleaning solution for 5 times; then 200 mul of Eu are added3+Labeled anti-mullerian hormone monoclonal antibody II, and performing shaking incubation at 25 ℃ for 5 min; repeating the above cleaning step 4 times with cleaning solution; adding 200 μ L of enhancing solution, and incubating at 25 deg.C for 5 min; and detecting by using a time-resolved fluorescence immunoassay analyzer.
Further, the coupling buffer was sodium carbonate buffer at a concentration of 0.2M, pH 8.3.3.
Further, the cleaning solution contains 8mmol/L NaCl, 0.1% BSA, 0.2% bovine serum albumin, 0.1mol/L Tween-80 and 0.1% NaN3Tris-HCl buffer (50mmol/L, pH 7.8).
Further, the blocking solution was 1% BSA in PBS buffer (0.02M, pH 7.4).
Further, the preservation solution was Tris-HCl buffer (0.05M, pH 8.0) containing 5% BSA, 10% trehalose, 0.1% Tween-20.
Furthermore, the enhancement liquid is a common brand on the market, and the brand is Jiangyuan.
Example 3
The time-resolved immunofluorescence analysis method is to label lanthanide onto antibody by using chelating agent with bifunctional group structure, and combine with antigen to form immune complex through immune reaction, because Eu is combined on immune complex3+The emitted fluorescence intensity is quite weak, and only the enhancement liquid is added, so that the lanthanide is dissociated from the compound and chelated by the chelating agent contained in the enhancement liquid to form a new chelate, and therefore, the lanthanide emits strong fluorescence under the excitation of ultraviolet light and the like, the enhancement effect can reach millions of times, the chelating agent in the enhancement liquid has direct influence on the detection result, the chelating agent is mostly beta-diketone, and the best effect is beta-NTA.
The example provides a method for preparing an enhancement solution: 6mL of 0.1mol/L potassium hydrogen phthalate is adjusted to pH 3.2 by glacial acetic acid, then 15 mu mol of purified beta-NTA, 50 mu mol of TOPO and 1mL of Triton X-100 are sequentially added, finally ultrapure water is added to the solution until the volume is up to 1L, the solution is uniformly stirred, and the solution is stored in dark at 4 ℃ for standby.
The commercially available beta-NTA (with the common purity of 99%) contains a large amount of chloride ions and metal ions, and the detection result is interfered.
Purification method of beta-NTA: placing beta-NTA in a round-bottom flask, adding 70% ethanol for dissolving, and placing in a constant temperature water bath at 70 deg.C for 20 min; filtering while hot to remove insoluble impurities; cooling the filtrate to separate out crystals, washing the crystals with absolute ethyl alcohol for many times, and finally drying the crystals to obtain the purified beta-NTA.
The embodiment provides a preparation method of enhancement solution, which is characterized in that the enhancement solution with high purity is prepared by purifying a chelating agent beta-NTA to improve the fluorescent rare earth ion Eu3+The accuracy of the detection result is further improved by the purpose of the luminous intensity.
This example is identical to example 1 except that the commercially available conventional strength-enhancing fluid was replaced with the high purity strength-enhancing fluid prepared in this example, and the results are shown in FIG. 1, where the high purity strength-enhancing fluid was counted to a maximum in about 12min and thereafter remained essentially unchanged, whereas the conventional strength-enhancing fluid was counted to a maximum in about 14min, but had much lower performance than the high purity strength-enhancing fluid.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (6)
1. A kit for quantitatively detecting the content of anti-mullerian hormone is characterized by comprising: NHS magnetic bead suspension, anti-mullerian hormone monoclonal antibody I, anti-mullerian hormone monoclonal antibody II, coupling buffer solution, sealing solution, enhancement solution, cleaning solution and calibrator; the preparation method of the enhancement solution comprises the steps of adjusting the pH value of 6mL of 0.1mol/L potassium hydrogen phthalate to 3.2 by using glacial acetic acid, sequentially adding 15 mu mol of purified beta-NTA, 50 mu mol of TOPO and 1mL of Triton X-100, finally adding ultrapure water to a constant volume of 1L, uniformly stirring, and carrying out dark preservation at 4 ℃ for later use; the purification method of the beta-NTA comprises the following steps: placing beta-NTA in a round-bottom flask, adding 70% ethanol for dissolving, and placing in a constant temperature water bath at 70 deg.C for 20 min; filtering while hot to remove insoluble impurities; cooling the filtrate to separate out crystals, washing the crystals with absolute ethyl alcohol for many times, and finally drying the crystals to obtain the purified beta-NTA.
2. The method for detecting the amount of anti-mullerian hormone contained in the kit according to claim 1, which comprises the following steps:
(1) diluting anti-mullerian hormone monoclonal antibody I with coupling buffer solution to the concentration of more than or equal to 20 ug/mL;
(2) putting 100 mu L of NHS magnetic bead suspension into a reaction tube, carrying out magnetic separation, reserving NHS magnetic beads, and discarding supernatant; add 500. mu.L of coupling buffer into the reaction tube and vortex for 15 s; performing magnetic separation, keeping NHS magnetic beads, and discarding supernatant;
(3) adding 1mL of diluted anti-mullerian hormone monoclonal antibody I into a reaction tube, vortexing for 30s, and uniformly mixing NHS magnetic beads; placing the reaction tube on a rotary mixer, and incubating for 2h at room temperature;
(4) after the incubation is finished, performing magnetic separation, discarding the supernatant, and keeping the NHS magnetic beads; adding 1mL of confining liquid into a reaction tube, swirling for 20s, placing the reaction tube on a rotary mixer, incubating for 1h at room temperature, performing magnetic separation, discarding the supernatant, and retaining NHS magnetic beads; finally, adding 1mL of cleaning solution into the reaction tube, carrying out vortex for 20s, carrying out magnetic separation, discarding the supernatant, and keeping the NHS magnetic beads; repeating the cleaning step for 1 time; obtaining magnetic beads coupled with anti-mullerian hormone monoclonal antibody I, adding a preservation solution, and preserving at 4 ℃ for later use;
(5) 500 mu L of anti-mullerian hormone monoclonal antibody II and 200 mu L of Eu are taken3+adding-DTPA into a reaction tube, and carrying out magnetic stirring reaction at 25 ℃ for 24h to obtain Eu3+Labeled anti-mullerian hormone monoclonal antibody II, Eu3+Purifying the marked anti-mullerian hormone monoclonal antibody II by using a protein column and storing for later use;
(6) sequentially adding magnetic beads coupled with anti-mullerian hormone monoclonal antibody I, 50 muL of calibrator or serum to be tested and 150 muL of Tris-HCL reaction buffer solution into a 96-hole microplate, carrying out oscillation incubation at 25 ℃ for 5min, standing for 2min, retaining the magnetic beads coupled with anti-mullerian hormone monoclonal antibody I, and discarding supernatant; repeating the above cleaning step with cleaning solution for 5 times; then 200 mul of Eu are added3+Labeled anti-mullerian hormone monoclonal antibody II, and performing shaking incubation at 25 ℃ for 5 min; repeating the above cleaning step with cleaning solution for 5 times; adding 200 μ L of enhancing solution, and incubating at 25 deg.C for 5 min; and detecting by using a time-resolved fluorescence immunoassay analyzer.
3. The method for detecting the amount of anti-mullerian hormone in a kit according to claim 2, wherein the coupling buffer is sodium carbonate buffer at a concentration of 0.2M, pH 8.3.3.
4. The method for detecting the non-disease diagnosis purpose of the kit for quantitatively detecting the content of anti-mullerian hormone according to claim 2, wherein the cleaning solution comprises 8mmol/L NaCl, 0.1% BSA, 0.2% BSA, 0.1mol/L Tween-80, and 0.1% NaN3Tris-HCl buffer (1).
5. The method for detecting the amount of anti-mullerian hormone contained in a kit according to claim 2, wherein the blocking solution is 1% BSA in PBS.
6. The method for detecting the non-disease diagnosis purpose of the kit for quantitatively detecting the content of anti-mullerian hormone according to claim 2, wherein the storage solution is Tris-HCl buffer solution containing 5% BSA, 10% trehalose and 0.1% Tween-20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910701278.4A CN110398589B (en) | 2019-08-17 | 2019-08-17 | Kit for quantitatively detecting content of anti-mullerian hormone and detection method thereof for non-disease diagnosis purpose |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910701278.4A CN110398589B (en) | 2019-08-17 | 2019-08-17 | Kit for quantitatively detecting content of anti-mullerian hormone and detection method thereof for non-disease diagnosis purpose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110398589A CN110398589A (en) | 2019-11-01 |
| CN110398589B true CN110398589B (en) | 2020-11-06 |
Family
ID=68326914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910701278.4A Active CN110398589B (en) | 2019-08-17 | 2019-08-17 | Kit for quantitatively detecting content of anti-mullerian hormone and detection method thereof for non-disease diagnosis purpose |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110398589B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112180104A (en) * | 2020-08-31 | 2021-01-05 | 浙江博实生物科技有限公司 | Time-resolved fluorescence immunoassay kit based on anti-mullerian hormone AMH, and preparation method and detection method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106053791A (en) * | 2016-06-30 | 2016-10-26 | 深圳市亚辉龙生物科技股份有限公司 | Anti-mullerian hormone chemiluminescence immunoassay kit and preparation method and application thereof |
| CN107561267A (en) * | 2017-07-11 | 2018-01-09 | 广东省湛江市质量计量监督检测所 | For capturing the NHS immunomagnetic beads preparation method and applications of vibrio parahemolyticus |
| CN108333370A (en) * | 2018-02-09 | 2018-07-27 | 广州源起健康科技有限公司 | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects cTnI kits |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101614741A (en) * | 2008-06-25 | 2009-12-30 | 上海新波生物技术有限公司 | Diagnostic kit for quantitatively detecting hepatitis B virus surface antigen |
| CN101614750A (en) * | 2008-06-25 | 2009-12-30 | 上海新波生物技术有限公司 | First-trimester down syndrome prenatal screening kit |
| CN105572358A (en) * | 2014-10-09 | 2016-05-11 | 苏州新波生物技术有限公司 | Hepatitis B virus e antigen quantitative detection kit, preparation method and detection method thereof |
-
2019
- 2019-08-17 CN CN201910701278.4A patent/CN110398589B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106053791A (en) * | 2016-06-30 | 2016-10-26 | 深圳市亚辉龙生物科技股份有限公司 | Anti-mullerian hormone chemiluminescence immunoassay kit and preparation method and application thereof |
| CN107561267A (en) * | 2017-07-11 | 2018-01-09 | 广东省湛江市质量计量监督检测所 | For capturing the NHS immunomagnetic beads preparation method and applications of vibrio parahemolyticus |
| CN108333370A (en) * | 2018-02-09 | 2018-07-27 | 广州源起健康科技有限公司 | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects cTnI kits |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110398589A (en) | 2019-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109917134B (en) | Calibrator stabilizer, detection kit for determining C peptide and detection method | |
| CN103033619B (en) | A kind of protein chip kit of comprehensive detection lung cancer marker and method | |
| CN104655843A (en) | Gastric cancer detecting method, reagent and gastric cancer detecting kit | |
| CN111175491A (en) | sBCMA magnetic particle chemiluminescence immunoassay kit and preparation method and application thereof | |
| CN109116038A (en) | Unbonded estriol chemiluminescence immune detection reagent kit and preparation method thereof | |
| EP3295174B1 (en) | Method for re-using test probe and reagents in an immunoassay | |
| US20090136973A1 (en) | Determination of short-chain srl alcohol dehydrogenase (dhrs4) as a biomarker for inflammations and infections | |
| CN110398589B (en) | Kit for quantitatively detecting content of anti-mullerian hormone and detection method thereof for non-disease diagnosis purpose | |
| CN109517670A (en) | A kind of Abbott Laboratories' chemical illumination immunity analysis instrument cleaning solution and preparation method thereof | |
| CN116773807A (en) | Method for detecting African swine fever virus by using time-resolved fluorescence immunoassay probe | |
| CN109239369A (en) | Corticotrophin assay kit and preparation method thereof | |
| CN110618280A (en) | Thyrotropin determination kit and preparation method thereof | |
| Dakubu et al. | Time-resolved pulsed fluorescence immunometric assays of carcinoembryonic antigen. | |
| CN109212196A (en) | A kind of kit of quick detection free estriol | |
| CN109212194B (en) | Kit for quantitatively detecting transtriiodothyronine | |
| US3822116A (en) | Reagent and method for calcium determination | |
| CN103123356A (en) | Time-resolved fluorescence comprehensive detection kit of uterine cancer and application thereof | |
| CN113109325A (en) | Pepsinogen I enzymatic chemiluminescence detection kit and preparation method and application thereof | |
| CN112198309A (en) | Chemiluminescence substrate detection kit with high sensitivity and stable signal | |
| CN112180104A (en) | Time-resolved fluorescence immunoassay kit based on anti-mullerian hormone AMH, and preparation method and detection method thereof | |
| JP5997446B2 (en) | Liquid reagent for immobilizing thyroid hormone and use thereof | |
| CN111024940A (en) | Time-resolved fluorescence immunoassay method based on gold magnetic particles | |
| CN209878780U (en) | Pepsinogen I detection kit | |
| CN205786663U (en) | Double labelling time resolved fluoro-immunoassay test kit based on PG magnetic particle | |
| CN104034906A (en) | Time-resolved immunofluorescence analysis method for beta-HCG (Human Chorionic Gonadotropin) detection and kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a kit for quantitative detection of anti Mullerian hormone and a detection method for non disease diagnosis purpose Effective date of registration: 20211224 Granted publication date: 20201106 Pledgee: Ningbo Yongcheng Rural Commercial Bank Co.,Ltd. Chengnan sub branch Pledgor: NINGBO AUCHEER BIOTECHNOLOGY CO.,LTD. Registration number: Y2021980016092 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |